Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study

Abstract Introduction The aim of this study was to evaluate the real-world outcomes of brolucizumab use in Japanese patients with neovascular age-related macular degeneration (nAMD). Methods PHEASANT was a retrospective, multicenter, single-arm cohort study. The study included 438 patients, of whom...

Full description

Saved in:
Bibliographic Details
Main Authors: Masayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, Kazuaki Kadonosono, Hitoshi Ohno, Ryusaburo Mori, Hidetaka Matsumoto, Ippei Nagamori, Yuki Murata, Tina Maio-Twofoot, Helene Karcher, Hidenori Takahashi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-05-01
Series:Ophthalmology and Therapy
Subjects:
Neovascular age-related macular degeneration
Real-world
Anti-VEGF
Brolucizumab
Retinal fluid
Online Access:https://doi.org/10.1007/s40123-025-01159-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40123-025-01159-2

Similar Items